Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Liquid Biopsy-based Genomic Assay to Enable Non-invasive Precision Diagnostics and Monitoring for Immune-mediated Lymphoproliferative Disorders (ILD)

NCT05803616 is registered in ClinicalTrials.gov with University Hospital, Geneva as lead sponsor.

NCT NCT05803616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05803616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Liquid Biopsy-based Genomic Assay to Enable Non-invasive Precision Diagnostics and Monitoring for Immune-mediated Lymphoproliferative Disorders (ILD)
Lead sponsor
University Hospital, Geneva
Phase
Observational
Overall status
Unknown status
Start date
May 23, 2022
Completion date
December 31, 2025
Enrollment
20 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoproliferative disorder following transplantation, lymphoproliferative disorders